Skip to main content

Table 4 Effect of different factors on statin expenditure changes*

From: Effective policy initiatives to constrain lipid-lowering drug expenditure growth in South Korea

 

2005

2006

2007

2008

2009

Average

Year-on-year increased statin expenditure rate (%)* (T)

 

35.92

26.90

11.60

14.99

21.97

Core medicines (year-to-year rates of increase: %, A)

 

46.62

23.61

2.32

14.17

18.24

  - Price (△P)

 

−7.18

−0.33

−0.22

−6.21

−2.98

  -Within-component mix (generic mix)

 

5.36

−2.12

−1.77

−2.06

−0.90

  -Between-component mix

 

4.54

0.83

0.10

1.19

1.36

      (Ingredient mix)

  - Volume (△Q)

 

47.94

32.21

5.04

21.58

23.48

New entrants (year-to-year rates of increase: %, B)

 

2.69

3.30

10.54

0.96

6.43

  - New molecular entities

 

0.00

0.00

0.00

0.00

0.00

  - New medicines

 

0.00

0.00

0.01

0.34

0.12

  - New generic medicines

 

1.87

3.23

10.53

0.30

5.13

  - Others

 

0.82

0.07

0.00

0.32

0.26

Exiting medicines (year-to-year rates of increase: %, C)

 

−13.39

0.00

−1.26

−0.14

−2.70

  1. *The drug expenditure was adjusted for inflation.